Dzherelo (Immunoxel) as adjunctive therapy to standard antituberculosis treatment in patients with pulmonary tuberculosis: a systematic review and meta-analysis of clinical trials

Table 2 Characteristics of included studies

Trials	Country	Study design	Number of participants	Intervention	Comparator	Ref
Arjanova et al.	Ukraine	Open-label trial	40 TB/HIV coinfected patients	Immunoxel with ATT	ATT alone	[15]
Arjonova et al.	Ukraine	Open-label trail	40 TB/HIV coinfected patients	Immunoxel with ATT	ATT alone	[6]
Batbold et al.	Ukraine and Mongolia	Double-blinded placebo controlled RCT	269 participants	Immunoxel with ATT	ATT with placebo	[5]
Efremenko et al.	Ukraine	Unblinded RCT	69 patients, 76.8% with TB and 23.2% with TB/HIV co-infection	Various Immunoxel formulations: sugar dragees, sugar-coated pills, gelatin pastilles and dried honey lozenges	Sugar-coated pills without Immunoxel	[7]
Zaitzeva et al.	Ukraine	Non-randomised controlled trial	75 newly PTB patients to assess the adjunct effect of Dzherelo on clinical outcomes and biochemical and blood parameters in patients with cavitary and infiltrating PTB	Immunoxel with ATT	ATT only	[8]
Zaitzeva et al.	Ukraine	Non-randomised controlled trial	66 patients of which 48 had MDR-TB	Immunoxel with ATT	ATT alone	[16]

ISSN: 2046-4053